Search alternatives:
table 2.2 » table 3.1, table 1.1
table 2.1 » table 3.1, table 1, table 11
table 2 » table 1
table 2.2 » table 3.1, table 1.1
table 2.1 » table 3.1, table 1, table 11
table 2 » table 1
|
|
by Hartmann, Katherine E., Hall, Susan A., Nanda, Kavita, Boggess, John F.
Published 2002
Published 2002
Agency for Healthcare Research and Quality (US)
|
|
by Hartmann, Katherine E., Hall, Susan A., Nanda, Kavita, Boggess, John F.
Published 2002
Published 2002
Agency for Healthcare Research and Quality (US)
|
|
by Guirguis-Blake, Janelle, Henderson, Jillian T., Perdue, Leslie A., Whitlock, Evelyn P.
Published 2017
Published 2017
Agency for Healthcare Research and Quality
|
|
by Guirguis-Blake, Janelle, Henderson, Jillian T., Perdue, Leslie A., Whitlock, Evelyn P.
Published 2017
Published 2017
Agency for Healthcare Research and Quality
|
|
by Guirguis-Blake, Janelle
Published 2018
“... control trials on the harms of vitamin D to prevent falls in older adults. Two investigators independently...”Published 2018
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
|
|
by Guirguis-Blake, Janelle
Published 2018
“... control trials on the harms of vitamin D to prevent falls in older adults. Two investigators independently...”Published 2018
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
|
|
by Patnode, Carrie D.
Published 2015
“... to the effectiveness and safety of electronic nicotine delivery systems (ENDS) (through March 1, 2015) and a search...”Published 2015
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
|
|
by Patnode, Carrie D.
Published 2015
“... to the effectiveness and safety of electronic nicotine delivery systems (ENDS) (through March 1, 2015) and a search...”Published 2015
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
|
|
by Guirguis-Blake, Janelle, Evans, Corinne V., Perdue, Leslie A., Bean, Sarah
Published 2022
“... to 1.03]). Absolute risk reductions in major CVD events in the trials ranged from 0.08 to 2.5 percent...”Published 2022
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
|
|
by Guirguis-Blake, Janelle, Evans, Corinne V., Redmond, Nadia, Lin, Jennifer
Published 2018
“...Two trials reported conflicting results on total or fatal hemorrhagic CVA risk with wide confidence...”Published 2018
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
|
|
by Guirguis-Blake, Janelle, Evans, Corinne V., Redmond, Nadia, Lin, Jennifer
Published 2018
“...Two trials reported conflicting results on total or fatal hemorrhagic CVA risk with wide confidence...”Published 2018
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
|
|
by Lin, Jennifer, Webber, Elizabeth M., Thomas, Rachel G.
Published 2022
“... across a range of patient outcomes. One of the two trials (n=114) evaluating the same exercise-focused...”Published 2022
Agency for Healthcare Research and Quality
|
|
by Guirguis-Blake, Janelle, Senger, Caitlyn A., Webber, Elizabeth M., Mularski, Richard.
Published 2016
“... positive only if both the CDQ and FEV1/FEV6 tests were positive. Sensitivity and specificity were 72 and 97...”Published 2016
Agency for Healthcare Research and Quality
|
|
by Guirguis-Blake, Janelle, Senger, Caitlyn A., Webber, Elizabeth M., Mularski, Richard
Published 2016
“... positive only if both the CDQ and FEV1/FEV6 tests were positive. Sensitivity and specificity were 72 and 97...”Published 2016
Agency for Healthcare Research and Quality